Neuroprotection in cerebrovascular disease

Bibliography

• JAIN KK: Neuroprotection. Jain PharmaBiotech Research & Documentation, Basel, Switzerland (2000b).
   Google Scholar
• ••An in-depth review of intrinsic mechanisms of neuroprotec-tion and various methods to protect against brain damage in various disorders of the CNS such as stroke, traumatic brain injury and neurodegenerative disorders. Pathophysiology of these disorders is discussed as a basis for neuroprotection. Markets for neuroprotectives and companies developing them are also described.
   Google Scholar
• JAIN KK: Nicaraven for the treatment of cerebralvasospasm in subarachnoid haemorrhage. Exp. Opin. Invest. Drugs (2000) (In Press).
   Google Scholar
• LARSSON E, NANOBASHVILI A, KOKAIA Z et al.: Evidencefor neuroprotective effects of endogenous brain-derived neurotrophic factor after global forebrain ischaemia in rats. J. Cereb. Blood Flow Metab. (1999) 19:1220–1228.
   PubMed Web of Science ®Google Scholar
• GUEGAN C, CEBALLOS-PICOT I, NICOLE A et al.: Recruit-ment of several neuroprotective pathways after permanent focal ischaemia in mice. Exp. Neurol. (1998) 154(2)371–380.
   Google Scholar
• DUNLOP J, ZALESKA M, ELIADOF S et al.: Excitatory amino acid transporters as emerging targets for central nervous system therapeutics. Emerging Ther. Targets (1999) 3:543–570.
   Google Scholar
• KATO H, KOGURE K: Biochemical and molecular characteristics of the brain with developing cerebral infarction. Cell Mol. Neurobiol (1999) 19:93–108.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Neurotrophic Factors. Jain PharmaBiotech Research & Documentation, Basel, Switzerland (2000b).
   Google Scholar
• JIANG N, FINKLESTEIN SP, DO T, CADAY CG, CHARETTE M, CHOPP M: Delayed intravenous administration of basic fibroblast growth factor (bEGF) reduces infarct volume in a model of focal cerebral ischaemia/reperfusion in the rat. J. Neurol Sci. (1996) 139:173–179.
   PubMed Web of Science ®Google Scholar
• KAWAMATA T, ALEXIS NE, DIETRICH WD, FINKLESTEIN SP: Intracisternal basic fibroblast growth factor (bEGF) enhances behavioural recovery following focal cerebral infarction in the rat. J. Cereb. Blood Flow Metab. (1996) 16:542–547.
   PubMed Web of Science ®Google Scholar
• MOYER JA, WOOD A, ZALESKA MM et al: Basic fibroblast growth factor: a potential therapeutic agent for the treatment of acute neurodegenerative disorders and vascular insufficiency. Exp. Opin. Ther. Patents (1998) 8:1425–1446.
   Web of Science ®Google Scholar
• AY H, AY I, KOROSHETZ WJ et al.: Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc. Dis. (1999) 9:131–135.
   PubMed Web of Science ®Google Scholar
• SCHABITZ WR, LI F, IRIE K et al.: Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischaemia. Stroke (1999) 30:427–432.
   PubMed Web of Science ®Google Scholar
• LIBERINI P, REUBEN M, CLARKE PB, CUELLO AC: Nerve growth factor treatment restores [311](2NB binding site density in adult rats subjected to cortical infarction. Neuroreport (1995) 6:419–420.
   PubMed Web of Science ®Google Scholar
• SCHABITZ WR, SCHWAB S, HACKE W: Intraventricular brain-derived neurotrophic factor reduces infarct size following focal cerebral ischaemia in rats. Cerebrovasc. Dis. (1997) 7 (Suppl. 1):78 (Abstract).
   Google Scholar
• CUEVAS P, CARCELLER F, REIMERS D, SAENZ DE TEJADA I, GIMENEZ-GALLEGO G: Acidic fibroblast growth factor rescues gerbil hippocampal neurons from ischaemic apoptotic death. NeuroL Res. (1998) 20:271–274.
   PubMed Web of Science ®Google Scholar
• PREHN JH, BACKHAUSS C, KRIEGELSTEIN J: Transforming growth factor-beta 1 prevents glutamate neurotoxicity in rat neocortical cultures and protects mouse neocortex from ischaemic injury in vivo. J. Cereb. Blood Flow Metab. (1993) 13:521–525.
   PubMed Web of Science ®Google Scholar
• LODDICK SA, LIU XJ, LU ZX et al.: Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. Proc. Natl. Acad. Sci. USA (1998) 95(4):1894–1898.
   PubMed Web of Science ®Google Scholar
• BRAUN JS, TUOMANEN El, CLEVELAND JL: Neuroprotec-tion by caspase inhibitors. Exp. Opin. Invest. Drugs (1999) 8:1599–1610.
   PubMedGoogle Scholar
• MARTINS LM, EARNSHAW WC: Apoptosis: alive and kicking in 1997. Trends in Cell Biology (1997) 7:111–114.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Textbook of Hyperbaric Medicine, 3rd edition. Hogrefe Sz Huber, Gottingen-Seattle, USA (1999).
   Google Scholar
• YANAMOTO H, NAGATA I, NAKAHARA I et al. Combination of intraischaemic and postischaemic hypothermia provides potent and persistent neuroprotection against temporary focal ischaemia in rats. Stroke (1999) 30:2720–2726.
   PubMed Web of Science ®Google Scholar
• SCHWAB S, SPRANGER M, ASCHOFF A et al.: Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology (1997) 48:762–767.
   PubMed Web of Science ®Google Scholar
• HALLIWELL B: Free-radicals and antioxidants - a personal view. Nutr. Rev. (1994) 52:253–265.
   PubMed Web of Science ®Google Scholar
• KAWAI H, NAKAI H, SUGA M et al.: Effects of a novel free radical scavenger, MCI-186, on ischaemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. (1997) 281:921–927.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischaemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• VAUGHAN CJ, DELANTY N: Neuroprotective properties of statins in cerebral ischaemia and stroke. Stroke (1999) 30:1969–1973.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Textbook of Gene Therapy. Hogrefe & Huber, Gottingen-Seattle, USA (1998b).
   Google Scholar
• GREENBERG DA: Gene-based therapy for stroke: preclinical perspectives. DN & P (1996) 9:517–523.
   Google Scholar
• JAIN KK: Stroke. D&MD/International Business Communi-cations, Southborough, Massachusetts, USA (1998a).
   Google Scholar
• THE EUROPEAN AD HOC CONSENSUS GROUP: Neuroprotection as initial therapy in acute stroke. Cerebrovasc. Dis. (1998) 8:59–72.
   PubMed Web of Science ®Google Scholar
• LUTSEP HL, CLARK WM: Neuroprotection in acute ischaemic stroke. Drugs R & D (1999) 1:3-8. Some of the information is outdated.
   Google Scholar
• SAPOLSKY RM, STEINBERG GK: Gene therapy using viral vectors for acute neurologic insults. Neurology (1999) 53:1922–1931.
   PubMed Web of Science ®Google Scholar
• HICKENBOTTOM SL, GROTTA J: Neuroprotective therapy. Semin. Neurol (1998) 18:485-492. Good review but some of the information is outdated.
   Google Scholar
• HO DY, SAYDAM TC, FINK SL et al.: Defective herpes virus vectors expressing the rat brain glucose transporter protect cultured neurons from necrotic insult. J. Neurochem. (1995) 65:842–850.
   PubMed Web of Science ®Google Scholar
• SHAFRON DH, SIMPKINS C, DAY AL et al.: NMDA-R1 antisense gene delivery into neurons. Stroke (1996) 27:174 (Abstract).
   Google Scholar
• XU DG, CROCKER SJ DOUCET J-P et al.: Elevation of neuronal expression of NAIP reduces ischaemic damage in the rat hippocampus. Nature Med. (1999) 3:997–1004.
   Google Scholar
• YENARI MA, FINK SL, SUN GH et al.: Gene therapy with 115P72 is neuroprotective in rat models of stroke and epilepsy. Ann. Neurol (1998) 44:584–591.
   PubMed Web of Science ®Google Scholar